# US 2013/0156767 A1 · Method for treating cachexia using antagonist antibodies against gdf-8

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156767 A1
- Document ID: US20130156767A1
- Status: Published application
- Kind: A1
- Application number: 13/693,995
- Filed: 2012-12-04
- Published: 2013-06-20
- Earliest claimed: 2005-08-19
- Assignees: Wyeth
- Inventors: Frank S. Walsh; Margaret M. Zaleska; David S. Howland; Lioudmila Tchistiakova; Riyez Karim; Pamela Kelley; Xiang-Yang Tan; Seung Poon Kwak; Menelas N. Pangalos
- Web page: https://patentgrep.com/patent/US20130156767A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/18: of the parathyroid hormones
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/24: against cytokines, lymphokines or interferons
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/475: Assays involving growth factors
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A method of treating cachexia in a mammal, comprising administering to a mammal in need of treatment for cachexia a therapeutically effective amount of a GDF-8 specific antibody or antigen binding fragment thereof, said antibody or fragment comprising:
an antibody variable heavy (VH) region comprising the first, second and third complementarity determining regions (CDR) from the VH region defined by the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7; and
an antibody variable light (VL) region comprising the first, second and third complementarity determining regions (CDR) from the VL region defined by the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:9.

### Claim 36 (depends on 35)

The method of claim 35, wherein VH CDR1 comprises SEQ ID NO:10 or SEQ ID NO:20, VH CDR2 comprises SEQ ID NO:11 or SEQ ID NO:21, VH CDR3 comprises SEQ ID NO:12, VL CDR1 comprises SEQ ID NO:13, VL CDR2 comprises SEQ ID NO:14, and VL CDR3 comprises SEQ ID NO:15.

### Claim 37 (depends on 35)

The method of claim 35, wherein the VH region of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7.

### Claim 38 (depends on 35)

The method of claim 35, wherein the VL region of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:9.

### Claim 39 (depends on 35)

The method of claim 35, wherein the VH region of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7 and the VL region of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:9.

### Claim 40 (depends on 35)

The method of claim 35, wherein the VH region of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:7 and the VL region of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:9.

### Claim 41 (depends on 35)

The method of claim 35, wherein said antibody or fragment is partially or fully humanized.

### Claim 42 (depends on 35)

The method of claim 35, wherein said antibody binds to GDF-8 with an affinity of about 10 nM or higher affinity.

### Claim 43 (depends on 35)

The method fragment of claim 35, wherein said fragment is selected from the group consisting of an Fd fragment, an Fab fragment, an F(ab′)2 fragment, an scFv fragment, and an Fv fragment.

### Claim 44 (depends on 35)

The method of claim 35, wherein said antibody or fragment further comprises an antibody constant heavy region from a human immunoglobulin subtype selected from the group consisting IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE and IgM.

### Claim 45 (depends on 44)

The method or fragment of claim 44, wherein the antibody constant heavy region is from human IgG1.

### Claim 46 (depends on 44)

The method of claim 44, wherein the constant heavy region of said antibody or fragment is modified to alter a constant region effector function.

### Claim 47 (depends on 45)

The method of claim 45, wherein said constant heavy region comprises the amino acid sequence of SEQ ID NO:19.

### Claim 48 (depends on 47)

The method of claim 47, wherein the amino acid sequence of SEQ ID NO:19 is modified at one or more residues altering a constant heavy region effector function.

### Claim 49 (depends on 47)

The method of claim 47, wherein the amino acid sequence of SEQ ID NO:19 is modified at least at residue 117 or 120 thereof to alter an Fc region effector function.

### Claim 50 (depends on 35)

The method of claim 35, wherein said antibody or fragment further comprises a human antibody kappa or lambda constant light region.

### Claim 51 (depends on 50)

The method of claim 50, wherein said constant light region comprises the amino acid sequence of SEQ ID NO:17.

### Claim 52

A method of treating cachexia in a mammal, comprising administering to a mammal in need of treatment for cachexia a therapeutically effective amount of a GDF-8 specific antibody comprising:
two antibody heavy chains, each comprising a variable heavy region defined by the amino acid sequence of SEQ ID NO:7 and the constant heavy region from human IgG1; and
two antibody light chains, each comprising a variable light region defined by the amino acid sequence of SEQ ID NO:9 and a constant light region defined by the amino acid sequence of SEQ ID NO:17.

### Claim 53 (depends on 52)

The method of claim 52, wherein said constant heavy region comprises the amino acid sequence of SEQ ID NO:19 modified at least at residue 117 or 120 thereof to alter an Fc region effector function.
